Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours
作者： P.A. Ellis , A. Norman , A. Hill , M.E.R. O'Brien , M. Nicolson
DOI: 10.1016/0959-8049(95)00323-B
关键词:
摘要: Hepatobiliary tumours are rare, often present late and have a poor prognosis, with no current effective systemic therapy available. This study aimed to evaluate the activity toxicity of epirubicin, cisplatin continuous infusional 5-fluorouracil (5-FU) (ECF) in patients these tumours. From March 1991 November 1993, 25 advanced biliary 7 hepatoma were treated epirubicin 50 mg/m2 60 intravenously (i.v.) day 1, each given every 21 days 5-FU 200 mg/m2/day as 24 h i.v. infusion throughout treatment course. 8 20 (40%) evaluable responded. Median duration response was 10 months. 2 (29%) The regimen well tolerated minimal haematological non-haematological toxicity. novel is active hepatobiliary
elsevier.com
sci-hub.se 参考文章(16)
J H Harvey, F P Smith, P S Schein, 5-Fluorouracil, mitomycin, and doxorubicin (FAM) in carcinoma of the biliary tract. Journal of Clinical Oncology. ,vol. 2, pp. 1245- 1248 ,(1984) , 10.1200/JCO.1984.2.11.1245
J J Lokich, J D Ahlgren, J J Gullo, J A Philips, J G Fryer, A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. Journal of Clinical Oncology. ,vol. 7, pp. 425- 432 ,(1989) , 10.1200/JCO.1989.7.4.425
Ching‐Lung Lai, Anna Suk‐Fong Lok, Pui‐Chee Wu, Gerald Chee‐Bunn Chan, Hsiang‐Ju Lin, None, Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer. ,vol. 62, pp. 479- 483 ,(1988) , 10.1002/1097-0142(19880801)62:3<479::AID-CNCR2820620306>3.0.CO;2-L
Elio Sciarrino, Rosa Giovanna Simonetti, Salvatore Le Moli, Luigi Pagliaro, Adriamycin treatment for hepatocellular carcinoma. Experience with 109 patients. Cancer. ,vol. 56, pp. 2751- 2755 ,(1985) , 10.1002/1097-0142(19851215)56:12<2751::AID-CNCR2820561205>3.0.CO;2-O
E. L. Kaplan, Paul Meier, Nonparametric Estimation from Incomplete Observations Springer Series in Statistics. ,vol. 53, pp. 319- 337 ,(1992) , 10.1007/978-1-4612-4380-9_25
Geoffrey Falkson, John M. Macintyre, Charles G. Moertel, Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer. Cancer. ,vol. 54, pp. 965- 969 ,(1984) , 10.1002/1097-0142(19840915)54:6<965::AID-CNCR2820540603>3.0.CO;2-X
K. J. Scanlon, E. M. Newman, Y. Lu, D. G. Priest, Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells Proceedings of the National Academy of Sciences of the United States of America. ,vol. 83, pp. 8923- 8925 ,(1986) , 10.1073/PNAS.83.23.8923
Stephen W. Hall, Robert S. Benjamin, William K. Murphy, Manuel Valdivieso, Gerald P. Bodey, Adriamycin, BCNU, ftorafur chemotherapy of pancreatic and biliary tract cancer. Cancer. ,vol. 44, pp. 2008- 2013 ,(1979) , 10.1002/1097-0142(197912)44:6<2008::AID-CNCR2820440607>3.0.CO;2-E
Geoffrey Falkson, John M. MacIntyre, Charles G. Moertel, Lewis A. Johnson, R. C. Scherman, Primary liver cancer. An eastern cooperative oncology group trial Cancer. ,vol. 54, pp. 970- 977 ,(1984) , 10.1002/1097-0142(19840915)54:6<970::AID-CNCR2820540604>3.0.CO;2-7
Murray M. Bern, Very Low Doses of Warfarin Can Prevent Thrombosis in Central Venous Catheters Annals of Internal Medicine. ,vol. 112, pp. 423- 428 ,(1990) , 10.7326/0003-4819-76-3-112-6-423